Section Arrow
Quote
ERNA.NASDAQ
- Ernexa Therapeutics Inc.
(Financial Status)
Quotes are at least 15-min delayed:2026/05/22 17:29 EDT
After Hours
Last
 12
+0.01 (+0.08%)
Bid
11.6
Ask
12
High 12 
Low 11.5003 
Volume 538 
Regular Hours (Closed)
Last
 11.99
-0.47 (-3.77%)
Day High 
12.67 
Prev. Close
12.46 
1-M High
15.88 
Volume 
83.48K 
Bid
11.6
Ask
12
Day Low
11.5 
Open
12.21 
1-M Low
3.1829 
Market Cap 
14.53M 
Currency 美元 
P/E 0.01 
%Yield -- 
10-SMA 10.96 
20-SMA 7.9 
50-SMA 6.52 
52-W High 91.5375 
52-W Low 3.1829 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
1,214.25/-1.18
Enterprise Value
14.81M
Balance Sheet
Book Value Per Share
5.88
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
GOVXGeoVax Labs Inc.3.64+0.89+32.36%-- 
After Hours 3.66 +0.02 +0.55%
MTVAMetaVia Inc.3.85+0.98+34.15%-- 
After Hours 3.55 -0.3 -7.79%
AKTXAkari Therapeutics Plc18.27+13.13+255.45%-- 
After Hours 13.61 -4.66 -25.51%
LIMNLiminatus Pharma Inc0.1694-0.0766-31.14%-- 
After Hours 0.163 -0.0064 -3.78%
IOVAIovance Biotherapeutics4.11+0.41+11.08%-- 
After Hours 4.09 -0.02 -0.49%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.